Liposomal nanomedicine for breast cancer therapy.

Liposomes are well-established nanocarriers for improving the therapeutic index of anticancer agents. A remarkable understanding in the pathophysiology of breast cancer progression has emerged with information on the involved specific biomolecules, which may serve as molecular targets for its therapy. Hormonal and nonhormonal receptors can both be exploited for targeting to breast cancer cells. Targeted delivery of cytotoxic drugs using liposomes is a novel approach for breast cancer therapy. In the present article, we summarize molecular targets present on the breast cancer cells. Recent developments in liposome-based delivery of bioactives for selective treatments of breast cancer are discussed. In addition, utilization of bioenvironmental conditions of tumor for liposome-based targeted delivery is also summed up.

[1]  A. Godwin,et al.  Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. , 2002, The American journal of pathology.

[2]  C. Redmond,et al.  Tumor nuclear grade, estrogen receptor, and progesterone receptor: Their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer , 2005, Breast Cancer Research and Treatment.

[3]  N. Brünner,et al.  S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Hortobagyi,et al.  Progress in breast cancer chemoprevention. , 2002, Endocrine-related cancer.

[5]  C. Yuichiro,et al.  Ph-sensitive liposomes , 1993 .

[6]  C. Benz,et al.  Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine , 2009, Cancer Chemotherapy and Pharmacology.

[7]  J. R. Abney,et al.  Lateral interactions among membrane proteins. Implications for the organization of gap junctions. , 1987, Biophysical journal.

[8]  K. Yamada,et al.  Integrin‐dependent signal transduction , 1996, Journal of cellular biochemistry.

[9]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[10]  R. Coombes,et al.  POSSIBLE ROLE FOR VITAMIN D IN CONTROLLING BREAST CANCER CELL PROLIFERATION , 1989, The Lancet.

[11]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[12]  Ronald G. Crystal,et al.  Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.

[13]  Samuel Zalipsky,et al.  Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.

[14]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[16]  A. Goyal,et al.  Solid Lipid Nanoparticles (SLNs) as a Rising Tool in Drug Delivery Science: One Step Up in Nanotechnology , 2008 .

[17]  F M Muggia,et al.  Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Amarnath Sharma,et al.  Liposomes in drug delivery: Progress and limitations , 1997 .

[19]  L. Schumaker,et al.  The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. , 1995, Cancer letters.

[20]  R. Perez-soler,et al.  Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer , 2000, Cancer Gene Therapy.

[21]  B. Elliott,et al.  Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  L. Seymour,et al.  Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression , 1991, Breast Cancer Research and Treatment.

[23]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[24]  J. Legendre,et al.  Delivery of Plasmid DNA into Mammalian Cell Lines Using pH-Sensitive Liposomes: Comparison with Cationic Liposomes , 1992, Pharmaceutical Research.

[25]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[26]  E. Chang,et al.  Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv , 2001, Molecular medicine.

[27]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[28]  Qiang Zhang,et al.  Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  A. Harris,et al.  Plasminogen activator inhibitor‐1 as a measure of vascular remodelling in breast cancer , 2001, The Journal of pathology.

[30]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[31]  T. Reynolds,et al.  Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[34]  J. Hagstrom,et al.  pH-sensitive, cationic liposomes: A new synthetic virus-like vector , 1996, Nature Biotechnology.

[35]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[36]  R. Elledge,et al.  Prognostic and predictive value of p53 and p21 in breast cancer , 2004, Breast Cancer Research and Treatment.

[37]  E. Milgrom,et al.  Thyroid hormone receptors in human breast cancer. , 1981, Cancer research.

[38]  A Valencia,et al.  The ras protein family: evolutionary tree and role of conserved amino acids. , 1991, Biochemistry.

[39]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[40]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[41]  D. Papahadjopoulos,et al.  pH‐sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules , 1985, FEBS letters.

[42]  J. Lohi.  Laminin‐5 in the progression of carcinomas , 2001, International journal of cancer.

[43]  S. Stass,et al.  Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. , 1999, Cancer research.

[44]  A. Ullrich,et al.  Breast cancer is associated with loss of the c‐kit oncogene product , 1992, International journal of cancer.

[45]  K. Ozono,et al.  Perspectives: The genomic mechanism of action of 1,25‐dihydroxyvitamin D3 , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  K. Gelmon,et al.  Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model , 2004, Cancer biology & therapy.

[47]  J. Kelsey.  A review of the epidemiology of human breast cancer. , 1979, Epidemiologic reviews.

[48]  R Blumenthal,et al.  Design of liposomes for enhanced local release of drugs by hyperthermia. , 1978, Science.

[49]  C. Heldin,et al.  Involvement of platelet-derived growth factor in disease: development of specific antagonists. , 2001, Advances in cancer research.

[50]  N. M. Rao,et al.  Haloperidol-associated Stealth Liposomes , 2005, Journal of Biological Chemistry.

[51]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[52]  A. Goyal,et al.  Targeted delivery of doxorubicin via estrone-appended liposomes , 2008 .

[53]  M. Hendrix,et al.  maspin suppresses the invasive phenotype of human breast carcinoma. , 1998, Cancer research.

[54]  J. Diebold,et al.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. , 1998, The American journal of pathology.

[55]  L. Shaw,et al.  Integrin Laminin Receptors and Breast Carcinoma Progression , 2001, Journal of Mammary Gland Biology and Neoplasia.

[56]  S. Litvinov,et al.  The epithelial sialomucin, episialin, is sialylated during recycling. , 1993, The Journal of biological chemistry.

[57]  David Needham,et al.  The materials engineering of temperature-sensitive liposomes. , 2004, Methods in enzymology.

[58]  E. Chan,et al.  Development of stealth liposome coencapsulating doxorubicin and fluoxetine , 2011, Journal of liposome research.

[59]  E. Chang,et al.  Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels , 2002, Molecular medicine.

[60]  John W. Park.  Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.

[61]  M. Hung,et al.  Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. , 1991, Oncogene.

[62]  P. Lala,et al.  Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis , 2001, International journal of cancer.

[63]  R. Perez-soler,et al.  Liposomes in the treatment of malignancy: a clinical perspective. , 1992, Critical reviews in oncology/hematology.

[64]  F. Szoka,et al.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. , 2001, Cancer research.

[65]  L. Riccardi,et al.  Effects of ALL‐trans‐retinoic acid and 13‐cis‐retinoic acid on breast‐cancer cell lines: Growth inhibition and apoptosis induction , 1997, International journal of cancer.

[66]  S. Jothy,et al.  Effect of hyaluronan on xenotransplanted breast cancer. , 2002, Experimental and molecular pathology.

[67]  M. Friedrich.  Cancer Drug Target , 2009 .

[68]  G. Nemerow,et al.  Urokinase Plasminogen Activator/Urokinase-specific Surface Receptor Expression and Matrix Invasion by Breast Cancer Cells Requires Constitutive p38α Mitogen-activated Protein Kinase Activity* , 2000, The Journal of Biological Chemistry.

[69]  W. Knudson,et al.  Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. , 1993, Journal of cell science.

[70]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[71]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[72]  Y. Har-el,et al.  Intracellular Delivery of Nanocarriers for Cancer Therapy , 2007 .

[73]  R. DiPaola,et al.  Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. , 1997, Cancer gene therapy.

[74]  Pauline Chu,et al.  A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. , 2004, International journal of radiation oncology, biology, physics.

[75]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[76]  E. Winer,et al.  Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  B. S. Reddy,et al.  17β‐Estradiol‐Associated Stealth‐Liposomal Delivery of Anticancer Gene to Breast Cancer Cells , 2005 .

[78]  Jose M. Silva,et al.  Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer , 2002, Oncogene.

[79]  N. Charnaux,et al.  Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1 , 2006, Journal of drug targeting.

[80]  M. Newman,et al.  Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. , 1999, The Journal of pharmacology and experimental therapeutics.

[81]  C. Arteaga,et al.  HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. , 2002, Seminars in oncology.

[82]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[83]  M. Seto,et al.  Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. , 1993, The American journal of pathology.

[84]  B. Weintraub,et al.  Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. , 1995, Human gene therapy.

[85]  N. Mishra,et al.  A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. , 2010, Current cancer drug targets.

[86]  T. Ishida,et al.  Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. , 2001, Biochimica et biophysica acta.

[87]  R. G. Anderson,et al.  Potocytosis: sequestration and transport of small molecules by caveolae. , 1992, Science.

[88]  Qiang Zhang,et al.  Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo , 2005, Pharmaceutical Research.

[89]  John Calvin Reed,et al.  Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. , 2000, Neoplasia.

[90]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[91]  S K Libutti,et al.  Progress in antiangiogenic gene therapy of cancer , 2000, Cancer.

[92]  T. Allen,et al.  Long-circulating, polyethylene glycol-grafted immunoliposomes , 1996 .

[93]  A. Giordano,et al.  CDK9: From Basal Transcription to Cancer and AIDS , 2002, Cancer biology & therapy.

[94]  D. Tzemach,et al.  Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  H. Harashima,et al.  Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. , 2007, International journal of pharmaceutics.

[96]  R. Banerjee,et al.  Liposomes: Applications in Medicine , 2001, Journal of biomaterials applications.

[97]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[98]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[99]  V. Moudgil,et al.  Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells , 2002, Oncogene.

[100]  S. Aaronson,et al.  Growth factors and cancer. , 1991, Science.

[101]  L. Gerweck,et al.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.

[102]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[103]  P. Keely.  Ras and Rho protein induction of motility and invasion in T47D breast adenocarcinoma cells. , 2001, Methods in enzymology.

[104]  Takashi Suzuki,et al.  Retinoic Acid Receptor and Retinoid × Receptor in Ductal Carcinoma in situ and Intraductal Proliferative Lesions of the Human Breast , 2000, Japanese journal of cancer research : Gann.

[105]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[106]  O. Katare,et al.  Liposomal drug delivery systems--clinical applications. , 2005, Acta pharmaceutica.

[107]  S. Merajver,et al.  Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. , 2002, The American journal of pathology.

[108]  S. Aliño,et al.  Human α1-Antitrypsin Gene Transfer to In Vivo Mouse Hepatocytes , 1996 .

[109]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[110]  A. Dritschilo,et al.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. , 1992, Nucleic acids research.

[111]  K. Wiman,et al.  p53-induced apoptosis as a safeguard against cancer. , 1999, Biochemical and biophysical research communications.

[112]  Stavroula Sofou,et al.  The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy. , 2009, Biomaterials.

[113]  M. Schwartz.  Integrins, Oncogenes, and Anchorage Independence , 1997, The Journal of cell biology.

[114]  M. Dewhirst,et al.  Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  R. Nicholson,et al.  Steroid hormone receptors and their clinical significance in cancer. , 1995, Journal of clinical pathology.

[116]  K. Iwai,et al.  Increased expression of DNA cointroduced with nuclear protein in adult rat liver. , 1989, Science.

[117]  A. J. Day,et al.  Hyaluronan-binding Proteins: Tying Up the Giant* , 2002, The Journal of Biological Chemistry.

[118]  M. Hung,et al.  HER-2/neu-targeting gene therapy--a review. , 1995, Gene.

[119]  R. Mahato.  Water insoluble and soluble lipids for gene delivery. , 2005, Advanced drug delivery reviews.

[120]  M. Dewhirst,et al.  Relationships among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. , 1992, International journal of radiation oncology, biology, physics.

[121]  G. Mcmahon,et al.  Receptor tyrosine kinases as targets for inhibition of angiogenesis , 1997 .

[122]  R. Pietras,et al.  Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells , 1977, Nature.

[123]  J. Sleeman,et al.  Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. , 1994, Current opinion in cell biology.

[124]  M. Israel,et al.  Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.

[125]  S. Rabbani,et al.  Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. , 2002, Cancer research.

[126]  J. O’Shaughnessy,et al.  Liposomal anthracyclines for breast cancer: overview. , 2003, The oncologist.

[127]  J. Kao,et al.  Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells , 2010, Breast Cancer Research and Treatment.

[128]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[129]  G. Gregoriadis,et al.  Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. , 1985, Biochimica et biophysica acta.

[130]  N. Rooijen,et al.  Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. , 1980 .

[131]  L. Cattel,et al.  Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. , 2009, Molecular pharmaceutics.

[132]  D. Sellitti,et al.  Nuclear thyroid hormone receptors in C3H/HeN mouse mammary glands and spontaneous tumors. , 1983, Cancer research.